On May 23, the Colorado Prescription Drug Affordability Board (PDAB or Board) became the first PDAB in the country to move toward capping the price of a drug by holding an upper payment limit (UPL) rulemaking hearing. Friday’s hearing marked the first hearing (of at least three), for the first drug (Enbrel), by the first state PDAB to try to implement this mechanism to control drug costs.
In advance of the May 23 PDAB meeting, Colorado BioScience Association (CBSA) and Biotechnology Innovation Organization (BIO) submitted a joint comment letter discussing our serious concerns regarding Colorado’s inadequate efforts to conduct a Cost-Benefit Analysis ahead of UPL rulemaking, which risks leading to policy decisions that are not based on evidence (our letter is available through the PDAB’s website here).
Amy Goodman, CBSA’s…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
